Literature DB >> 8495427

Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation.

J A Nagy1, K T Herzberg, J M Dvorak, H F Dvorak.   

Abstract

Initiating events leading to the accumulation of malignant ascites in the peritoneal cavity were investigated in two syngeneic transplantable murine ascites-producing tumors, MOT mouse ovarian tumor and the TA3/St mammary carcinoma. The transport of two tracers, 125I-labeled human serum albumin (125I-HSA) and 51Cr-labeled red blood cells (51Cr-RBC), into and out of the peritoneal cavity was studied at early times after i.p. tumor cell injection, prior to abundant fluid accumulation, and at intervals of 5 to 360 min after i.v. or i.p. tracer injection. Tracer influx and efflux rates were estimated from the mass of tracer passing into or out of the peritoneal cavity following a bolus injection of tracer into either the blood or the peritoneal cavity. Efflux of 125I-HSA from the peritoneal cavity was markedly reduced (3- to 5-fold) within 1 day of i.p. injection of either type of tumor cell. Significantly reduced efflux preceded any increase in tumor cell number and by itself did not induce peritoneal fluid accumulation. 125I-HSA tracer influx from plasma to peritoneal fluid did not increase detectably until 5 to 7 days after tumor cell injection, when the tumor cell number had increased by 10- to 100-fold. Only at relatively late stages of ascites tumor growth, when the flow rate into the peritoneal cavity had increased relative to the flow rate out of the peritoneum, was there net peritoneal fluid accumulation. Thus, increased influx, in addition to impaired efflux, were required for malignant ascites accumulation. Following i.p. injection, the efflux rates of 125I-HSA always exceeded those of 51Cr-RBC, even in ascites tumor-bearing animals. Furthermore, 125I-HSA tracer disappeared from the peritoneal cavity more rapidly than it appeared in the plasma, suggesting that 125I-HSA moves more rapidly through the channels by which 51Cr-RBC egress from the peritoneum (primarily diaphragmatic lymphatics) and/or has access to additional pathways not open to 51Cr-RBC. Finally, flow rates into and out of the blood and peritoneum were used to obtain kinetic parameters that characterized tracer transport: k1, the rate constant for tracer transport from the blood to the peritoneum; k2, the rate constant for tracer transport from the peritoneal cavity to the blood; and k6, the rate constant for tracer transport from the peritoneal cavity to surrounding interstitial tissue.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495427

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

2.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

3.  PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors.

Authors:  Marcela A Haro; Chad A Littrell; Zhaojun Yin; Xuefei Huang; Karen M Haas
Journal:  Cancer Immunol Res       Date:  2016-11-08       Impact factor: 11.151

4.  SDF1/CXCL12 is involved in recruitment of stem-like progenitor cells to orthotopic murine malignant mesothelioma spheroids.

Authors:  Bonnie W Lau; Agnes B Kane
Journal:  Anticancer Res       Date:  2010-06       Impact factor: 2.480

Review 5.  Cytokines in tumour growth, migration and metastasis.

Authors:  R P Negus; F R Balkwill
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

6.  Phenotypic variations and differential migration of NIH:OVCAR-3 ovarian carcinoma cells isolated from athymic mice.

Authors:  A L Veatch; L F Carson; S Ramakrishnan
Journal:  Clin Exp Metastasis       Date:  1995-05       Impact factor: 5.150

Review 7.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

8.  A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Hatem Elalfy; Tarek Fouad Sheta; Mahmoud Awad; Mostafa Abdelsalam; Rania Elhelaly; Rasha Elzehery; Nawal S Gouda; Waleed Eldars
Journal:  J Gastrointest Cancer       Date:  2017-03

Review 9.  Vascular permeability factor (VPF, VEGF) in tumor biology.

Authors:  D R Senger; L Van de Water; L F Brown; J A Nagy; K T Yeo; T K Yeo; B Berse; R W Jackman; A M Dvorak; H F Dvorak
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

10.  Activation of B-1 Cells Promotes Tumor Cell Killing in the Peritoneal Cavity.

Authors:  Marcela A Haro; Allison M Dyevoich; James P Phipps; Karen M Haas
Journal:  Cancer Res       Date:  2018-09-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.